Biohaven Pharmaceutical Holding Co. Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (13)

Latest Posts

About This Stock More About This Stock
The Week Ahead In Biotech: Pharma Earnings Pick Up Pace
Article By: Benzinga
Saturday, July 20, 2019 8:56 PM EST
Biotech stocks had a relatively muted performance last week. Johnson & Johnson kickstarted the second-quarter reporting season for big pharma companies, beating forecasts and an upward adjustment to its full-year sales guidance.
In this article: BMY, DGX, EW, JNJ, MRK, ANIK, BIIB, CELG, BHVN
Read
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Article By: Benzinga
Saturday, April 27, 2019 6:05 PM EST
Biotech stocks staged a recovery this week after being in the red in the previous two weeks.
In this article: BTX, BOLD, REGN, BIIB, GWPH, ALDX, HRTX, IONS, ADAP, NBRV, BHVN, NVS, SNY, RHHBY, ABBV
Read
Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals
Article By: ChinaBio® Today
Sunday, January 13, 2019 1:18 PM EST
China's life science sector started off 2019 with $425 million from ten deals involving Apollomics, Schrödinger of New York City and BrightGene Bio-Medical of Suzhou, among others.
In this article: NVS, SPRO, CBMG, BHVN, ASLN
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Biohaven Says Two Phase 3 Clinical Trials For Migraine Met Efficacy Endpoints
Article By: The Fly
Monday, March 26, 2018 6:27 AM EST
Biohaven Pharmaceutical announced positive top-line results from both of its two Phase 3 clinical trials of rimegepant, an oral CGRP receptor antagonist for the acute treatment of migraine.
In this article: BHVN
Read

PARTNER HEADLINES

Latest Tweets for $BHVN

No tweets yet!